SecBot SecBot
8-K ·Filed Mar 11, 2026

CERO

CERO THERAPEUTICS HOLDINGS, INC.
BEARISH
Impact 7/10
Horizonweeks Processed8mo ago SEC0001213900-26-025817
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

Monitor for rapid share price decline as the conversion mechanism creates downward pressure; watch for registration statement filing which will enable resale of conversion shares; assess whether this financing indicates cash flow distress given the high-cost terms

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.0350
T+0 close · Mar 11, 2026 · via day close
Latest settled
−65.71%
T+60 · $0.0120
Vs SPY
−77.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $0.0350entry
  2. T+1 · 8mo ago 0.00%α +1.48% · $0.0350
  3. T+5 · 8mo ago −5.71%α −3.53% · $0.0330
  4. T+20 · 7mo ago −2.86%α −3.38% · $0.0340
  5. T+60 · 6mo ago −65.71%α −77.24% · $0.0120

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CERO Therapeutics raised $750,000 through a convertible promissory note with a principal of $937,500, bearing 10% interest and maturing August 6, 2027. The note is convertible into common stock at a discount (80% of the 5 lowest intraday prices over 20 days) or $0.05, whichever is lower, creating immediate dilution risk and increasing leverage.

Key Financial Metrics

Deal Value
$750.0K
Premium
25%
Deal Type
credit_facility

Key Facts

  • Raised $750,000 in exchange for a convertible note with $937,500 principal (25% premium)
  • Note bears 10% annual interest and matures in August 2027
  • Conversion price is the lesser of $0.05 or 80% of the 5 lowest intraday prices over 20 days prior to conversion
  • Company must file registration statement for resale of conversion shares
  • Unregistered private placement to accredited investor under Rule 506(b)

Financial Impact

$750,000 in new debt with significant dilution risk due to discount conversion and 25% premium

debtdilutionequity_value

Risk Factors

  • Significant dilution from discount-based conversion formula
  • High interest rate (10%) increases financial burden
  • Potential for death spiral financing if share price declines
  • Registration requirement may flood market with new shares

Market Snapshot

Exchange
OTC

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-025817
Document: 0001213900-26-025817-index-headers.html0001213900-26-025817
Document: 0001213900-26-025817-index.html0001213900-26-025817
Document: 0001213900-26-025817.txt0001213900-26-025817

Track record

5 reports on CERO

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +40.00% at T+60 after the Jul 13, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Oct 7, 20265w ago 8-K Bearish 6/10 Entry $0.0951 Now $0.005000 +94.74% No price data
  2. Aug 31, 202611w ago 8-K Bearish 7/10 Entry $0.0120 to $0.0105 Now $0.005000 +58.33% ▲ +12.50% +13.68% vs SPY
  3. Jul 13, 202618w ago 25-NSE Bearish 7/10 Entry $0.0150 to $0.0100 Now $0.005000 +66.67% ▲ +33.33% +36.52% vs SPY
  4. Jun 26, 202620w ago 8-K Bearish 6/10 Entry $0.0110 to $0.009700 Now $0.005000 +54.55% ▲ +11.82% +11.56% vs SPY
  5. Mar 11, 202635w ago 8-K Bearish 7/10 Viewing Entry $0.0350 to $0.0340 Now $0.005000 +85.71% ▲ +2.86% +3.38% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 6h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026